NECLF logo

Nectar Lifesciences BDL:NECLF Stock Report

Last Price

US$0.40

Market Cap

US$87.7m

7D

-6.2%

1Y

9.4%

Updated

25 Nov, 2024

Data

Company Financials

Nectar Lifesciences Limited

BDL:NECLF Stock Report

Market Cap: US$87.7m

NECLF Stock Overview

Manufactures and sells pharmaceutical products in India and internationally. More details

NECLF fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance2/6
Financial Health4/6
Dividends0/6

Rewards

Trading at 65.2% below our estimate of its fair value

Became profitable this year

Risk Analysis

Interest payments are not well covered by earnings

Earnings have declined by 7.2% per year over past 5 years

Highly volatile share price over the past 3 months compared to the Luxembourg market

Does not have a meaningful market cap ($7B)


Nectar Lifesciences Limited Competitors

Domesco Medical Import - Export

HOSE:DMC

₫2.2t

Wanbury

BSE:524212

₹7.3b

Albert David

BSE:524075

₹7.3b

BioSyent

TSXV:RX

CA$130.4m

Price History & Performance

Summary of all time highs, changes and price drops for Nectar Lifesciences
Historical stock prices
Current Share Price₹0.40
52 Week High₹0
52 Week Low₹0
Beta1.03
11 Month Change-1.00%
3 Month Change-18.52%
1 Year Change9.39%
33 Year Change25.32%
5 Year Change126.29%
Change since IPO-47.89%

Recent News & Updates

Recent updates

Shareholder Returns

NECLFLU PharmaceuticalsLU Market
7D-6.2%0%0%
1Y9.4%0%0%

Return vs Industry: NECLF exceeded the Luxembourg Pharmaceuticals industry which returned 6.6% over the past year.

Return vs Market: NECLF exceeded the Luxembourg Market which returned 1% over the past year.

Price Volatility

Is NECLF's price volatile compared to industry and market?
NECLF volatility
NECLF Average Weekly Movement8.2%
Pharmaceuticals Industry Average Movement0%
Market Average Movement0%
10% most volatile stocks in LU Market0%
10% least volatile stocks in LU Market0%

Stable Share Price: NECLF's share price has been volatile over the past 3 months compared to the Luxembourg market.

Volatility Over Time: NECLF's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of Luxembourg stocks.

About the Company

FoundedEmployeesCEOWebsite
19951,686Amit Chadahwww.neclife.com

Nectar Lifesciences Limited manufactures and sells pharmaceutical products in India and internationally. The company’s active pharmaceutical ingredients and intermediates comprise cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium, ceftriaxone sodium, cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil and sterile, cefprozil, cefdinir, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate, and cefepime +Arginine. It also offers contract manufacturing for finished dosage forms, such as tablets, capsules, dry powder oral suspensions, and granules and injectable for cephalosporins.

Nectar Lifesciences Limited Fundamentals Summary

How do Nectar Lifesciences's earnings and revenue compare to its market cap?
NECLF fundamental statistics
Market capUS$87.68m
Earnings (TTM)US$1.27m
Revenue (TTM)US$199.25m

68.9x

P/E Ratio

0.4x

P/S Ratio

Is NECLF overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NECLF income statement (TTM)
Revenue₹16.79b
Cost of Revenue₹11.69b
Gross Profit₹5.11b
Other Expenses₹5.00b
Earnings₹107.27m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.48
Gross Margin30.40%
Net Profit Margin0.64%
Debt/Equity Ratio58.4%

How did NECLF perform over the long term?

See historical performance and comparison